Sonic Augmentation TechnologyTechnOXYNCT07276152
Plasma Oxytocin Changes in Response to Music Modified by Sonic Augmentation Technology
A study testing sonic augmentation technology in people with Sonic Augmentation Technology, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
The investigator aim to investigate wheather music modified by sonic augmentation technology can produce increasing oxytocin levels with minimal to no side effects in a highly standardized setting Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sonic Augmentation Technology
- What is being tested?
- sonic augmentation technology
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 1 siteSwitzerland
- Study dates
- 9 Jan 2026to Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult healthy controls
- No medication, except hormonal contraception
- Confirmed diagnosis of AVP-Deficiency
- Age ≥ 18 years
Who cannot join
- Participation in a trial with investigational drugs within 30 days
- Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
- Consumption of alcoholic beverages >15 drinks/week
- Tobacco smoking >10 cigarettes/day
- Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)
- Psychotic disorder in first-degree relatives
Show all 15Show fewer
- Pregnancy and breastfeeding
- Part 2:
- Participation in a trial with investigational drugs within 30 days
- Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
- Consumption of alcoholic beverages >15 drinks/week
- Tobacco smoking >10 cigarettes/day
- Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)
- Psychotic disorder in first-degree relatives
- Pregnancy and breastfeeding
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
University Hospital Basel
Basel, 4031
Mirjam Christ-Crain, Prof., +41 61 265 25 25, Mirjam.Christ-Crain@usb.ch
Mirjam Christ-Crain, Prof.
About this study
Official title: Plasma Oxytocin Changes in Response to Music Modified by Sonic Augmentation Technology vs Unaugmented Control Music in Healthy Controls and Patients With AVP-Deficiency
The investigator aim to investigate wheather music modified by sonic augmentation technology can produce increasing oxytocin levels with minimal to no side effects in a highly standardized setting
- Conditions
- Sonic Augmentation Technology
- Being tested
- sonic augmentation technology
- Keywords
- Arginine Vasopressin Deficiency, oxytocin, diabetes insipidus
- Medical subject headings
- Diabetes Insipidus, Neurogenic, Diabetes Insipidus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sonic augmentation technologyOther
Participants/ patients listen to music enhanced with sonic aumentation technology
| Study group | Role | What they receive |
|---|---|---|
| Sonic augmentation technology (SAT) - placebo music | Experimental | Participants will listen to music enhanced with SAT in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to placebo music Receives: Other: sonic augmentation technology |
| placebo music- sonic augmentation technology (SAT) music | Experimental | Participants will listen to placebo in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to music enhanced with SAT Receives: Other: sonic augmentation technology |
| Sonic augmentation technology (SAT) in patients | Experimental | Patients have one study visit listening to SAT Receives: Other: sonic augmentation technology |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in oxytocin levels in healthy adults after listening to SAT enhanced music vs. placebo music
Oxytocin release in response to music enhanced with SAT in healthy participants compared to oxytocin release in response to placebo stimulation in healthy participants
Measured: up to 30 min
Change in oxytocin levels in patients with AVP-deficiency after listening to SAT enhanced music
baseline is defined as 100% of the initial value, in patients with AVP-Deficiency. Any changes will be expressed as a percentage relative to this baseline. Maximum oxytocin level observed between baseline and 30 minutes will be determined.
Measured: up to 30 minutes
Secondary outcomes (16)
Area under the concentration time curve in plasma oxytocin
will be assessed for music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT
Measured: up to 30 minutes
Peak change in plasma oxytocin
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT
Measured: up to 30 minutes
Time course of plasma oxytocin levels
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT
Measured: up to 30 minutes
Time course of plasma copeptin
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT
Measured: up to 30 minutes
Time course of plasma cortisol
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT
Measured: up to 30 minutes
Time course of plasma neurophysin-1
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT
Measured: up to 30 minutes
Time course of other pituitary hormones/biomarkers
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT
Measured: up to 30 minutes
Subjective/emotional effects assessed on numeric rating scale (NRS)
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT.
NRS will be presented as a range from 0 to 10 marked with "not at all" on the left and "extremely" on the right. The following NAS will be used: "any effect", "good effect", "bad effect", "liking", "high", "happy", "fear", "stimulated", "feeling close to others", "concentration", "thinking", "open", "trust", "want to be with other people", "loss of sense of time", and "the boundaries between myself and my surroundings seemed to blur".
Measured: up to 30 minutes
Anxiety level using State-Trait Anxiety Inventory (STAI - State)
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency. Baseline (before lisening to SAT) to 35 min after listening to SAT.
Based on responses to 20 items, with scores ranging from 1 ("almost never") to 4 ("almost always"), a total score is calculated. The total trait score (STAI-T) ranges from 20 to 80, with higher scores indicating more pronounced anxiety and scores.
Measured: up to 35 minutes
Frequency of specific body stress reactions using the Body Perception Questionnaire Short Form (BPQ-SF)
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 50 min after listening to SAT.
The BPQ-SF will be used to assess the frequency of specific body stress reactions in organs that are innervated by the autonomic nervous system (ANS).
This study uses the Short Form (SF), totaling 46 items ranked from 1 (Never) to 5 (Always) to measure the frequency of specific body stress reactions. Though each unique part of the body may have its own reason for activation, the parts are linked by the ANS, a brain-body network that responds to everyday stress. Combined scores from organs throughout the body provide a measure of autonomic stress response patterns.
Measured: up to 50 minutes
Recognition of emotions and body expressions in the EmBody/EmFace task
will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 35 min after listening to SAT.
The EmBody and EmFace subtasks comprise each of 42 stimuli showing body or facial expressions of angry, happy, or neutral affect (14 clips per emotion, half in front view and half in half-profile side view from the left). Stimuli last 1.5 seconds at 24 frames per second and are geometrically and optically standardized to prevent biases induced by ethnic cues (e.g., hair or skin tone) or clothing. Item order is pseudorandom to prevent sequence effects and was determined using the following constraints: the same emotion is shown no more than twice in a row; the same view per emotion is not shown consecutively (i.e., no angry-front, angry-front).
Measured: up to 35 minutes
Assessment of blood pressure
safety assessment of systolic and diastolic blood pressure. Safety outcomes will be summarized using descriptive statistics.
Measured: up to 40 minutes
Assessment of heart rate
Saftey assessment of heart rate. Safety outcomes will be summarized using descriptive statistics.
Measured: up to 40 minutes
Assessment of body temperature
Safety assessment of body temperature. Safety outcomes will be summarized using descriptive statistics.
Measured: up to 40 minutes
Assessment of plasma potassium
Safety assessment of plasma potassium. Safety outcomes will be summarized using descriptive statistics
Measured: up to 30 minutes
Assessment of plasma sodium
Safety assessment of plasma sodium. Safety outcomes will be summarized using descriptive statistics.
Measured: up to 30 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2025
- Study start9 Jan 2026
- Primary completionAug 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sonic Augmentation TechnologyStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Part 1 is a double-blinded, randomized and cross-over proof-ofconcept trial Part 2 is an open-labeled single arm pilot study
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 22 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mirjam Christ-Crain, Prof., Principal investigator, University Hospital, Basel, Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07276152
- Sponsor's protocol ID
- 2025-01817, kt25christcrain6
- Other IDs
- 2025
- Acronym
- TechnOXY
- Status last verified
- Feb 2026
- First submitted
- 28 Nov 2025
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Plasma Oxytocin Changes in Response to Music Modified by Sonic Augmentation Technology vs Unaugmented Control Music in Healthy Controls and Patients With AVP-Deficiency
- ClinicalTrials.gov ID
- NCT07276152
- Acronym / sponsor ID
- TechnOXY / 2025-01817, kt25christcrain6
- Conditions
- Sonic Augmentation Technology
- Keywords
- Arginine Vasopressin Deficiency, oxytocin, diabetes insipidus
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 22 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 9 Jan 2026 (actual)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 10 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigator aim to investigate wheather music modified by sonic augmentation technology can produce increasing oxytocin levels with minimal to no side effects in a highly standardized setting
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
- Model description
- Part 1 is a double-blinded, randomized and cross-over proof-ofconcept trial Part 2 is an open-labeled single arm pilot study
| Arm | Type | Receives |
|---|---|---|
| Sonic augmentation technology (SAT) - placebo music | Experimental | Other: sonic augmentation technologyParticipants will listen to music enhanced with SAT in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to placebo music |
| placebo music- sonic augmentation technology (SAT) music | Experimental | Other: sonic augmentation technologyParticipants will listen to placebo in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to music enhanced with SAT |
| Sonic augmentation technology (SAT) in patients | Experimental | Other: sonic augmentation technologyPatients have one study visit listening to SAT |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult healthy controls
- No medication, except hormonal contraception
- Confirmed diagnosis of AVP-Deficiency
- Age ≥ 18 years
Key exclusion criteria (15 listed)
- Participation in a trial with investigational drugs within 30 days
- Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
- Consumption of alcoholic beverages >15 drinks/week
- Tobacco smoking >10 cigarettes/day
- Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sonic augmentation technologyParticipants/ patients listen to music enhanced with sonic aumentation technology | Other | Sonic augmentation technology (SAT) - placebo music, Sonic augmentation technology (SAT) in patients, placebo music- sonic augmentation technology (SAT) music |
Primary outcome
Change in oxytocin levels in healthy adults after listening to SAT enhanced music vs. placebo music
Time frame: up to 30 min
Oxytocin release in response to music enhanced with SAT in healthy participants compared to oxytocin release in response to placebo stimulation in healthy participants
Change in oxytocin levels in patients with AVP-deficiency after listening to SAT enhanced music
Time frame: up to 30 minutes
baseline is defined as 100% of the initial value, in patients with AVP-Deficiency. Any changes will be expressed as a percentage relative to this baseline. Maximum oxytocin level observed between baseline and 30 minutes will be determined.
16 secondary outcomes
Area under the concentration time curve in plasma oxytocin
Time frame: up to 30 minutes
Peak change in plasma oxytocin
Time frame: up to 30 minutes
Time course of plasma oxytocin levels
Time frame: up to 30 minutes
Time course of plasma copeptin
Time frame: up to 30 minutes
Time course of plasma cortisol
Time frame: up to 30 minutes
Time course of plasma neurophysin-1
Time frame: up to 30 minutes
Time course of other pituitary hormones/biomarkers
Time frame: up to 30 minutes
Subjective/emotional effects assessed on numeric rating scale (NRS)
Time frame: up to 30 minutes
Anxiety level using State-Trait Anxiety Inventory (STAI - State)
Time frame: up to 35 minutes
Frequency of specific body stress reactions using the Body Perception Questionnaire Short Form (BPQ-SF)
Time frame: up to 50 minutes
Recognition of emotions and body expressions in the EmBody/EmFace task
Time frame: up to 35 minutes
Assessment of blood pressure
Time frame: up to 40 minutes
Assessment of heart rate
Time frame: up to 40 minutes
Assessment of body temperature
Time frame: up to 40 minutes
Assessment of plasma potassium
Time frame: up to 30 minutes
Assessment of plasma sodium
Time frame: up to 30 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mirjam Christ-Crain, Prof. principal investigator
University Hospital, Basel, Switzerland
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing sonic augmentation technology in people with Sonic Augmentation Technology, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mirjam Christ-Crain, Prof. (+41 61 265 25 25, Mirjam.Christ-Crain@usb.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in oxytocin levels in healthy adults after listening to SAT enhanced music vs. placebo music (time frame: up to 30 min). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.